ArticleAIDS (London, England)2013
Disparities in the treatment and outcomes of lung cancer among HIV-infected individuals.
Article in AIDS (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Cancer disparities in people with HIV: A systematic review of screening for non-AIDS-defining malignancies.Cancer · 2019Pooled it
- Human immunodeficiency virus infection and mortality risk among lung cancer patients: A systematic review and meta-analysis.Medicine · 2018Pooled it
- Sex- and age- specific lung cancer incidence and mortality among Medicaid beneficiaries with and without HIV, 2001-2015.BMC cancer · 2026Article
- Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate Cancers.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Inequities by race and ethnicity in cancer treatment receipt among people living with HIV and cancer in the U.S. (2004-2020).BMC cancer · 2025Article
- Inequities in palliative care delivery to patients with HIV and stage IV cancers in the United States (2004-2020).JNCI cancer spectrum · 2025Article
- The Use of a Tailored Decision Aid to Improve Understanding of Lung Cancer Screening in People With HIV.Chest · 2025Observational
- HIV and lung cancer: a single cancer center experience.Frontiers in oncology · 2025Article
- Cancer Treatment Disparities in People With HIV in the United States, 2001-2019.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
- HIV Associated Lung Cancer: Unique Clinicopathologic Features and Immune Biomarkers Impacting Lung Cancer Screening and Management.Clinical lung cancer · 2024Article
- State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI.International journal of cancer · 2024Review
- Mortality due to non-AIDS-defining cancers among people living with HIV in Spain over 18 years of follow-up.Journal of cancer research and clinical oncology · 2023Article
- Cancer treatment delays among cancer patients living with HIV during the COVID-19 pandemic in the United States.Cancer medicine · 2023Article
- Research Priorities for Interventions to Address Health Disparities in Lung Nodule Management: An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2023Article
- Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are diagnosed with non-Hodgkin lymphoma: population-based analyses from the state of Georgia.Leukemia & lymphoma · 2023Article
- Palliative Care Use Among People Living With HIV and Cancer: An Analysis of the National Cancer Database (2004-2018).JCO oncology practice · 2022Article
- Safe performance of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with HIV infection.Cancer reports (Hoboken, N.J.) · 2022Article
- Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy.JCO global oncology · 2022Article
- The effect of non-AIDS-defining cancers on people living with HIV.The Lancet. Oncology · 2021Review
- Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.Current HIV/AIDS reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
objectivesHIV-infected people have elevated risk for lung cancer and higher mortality following cancer diagnosis than HIV-uninfected individuals. It is unclear whether HIV-infected individuals with lung cancer receive similar cancer treatment as HIV-uninfected individuals. DESIGN/
methodsWe studied adults more than 18 years of age with lung cancer reported to the Texas Cancer Registry (N = 156 930) from 1995 to 2009. HIV status was determined by linkage with the Texas enhanced HIV/AIDS Reporting System. For nonsmall cell lung cancer (NSCLC) cases, we identified predictors of cancer treatment using logistic regression. We used Cox regression to evaluate effects of HIV and cancer treatment on mortality.
resultsCompared with HIV-uninfected lung cancer patients (N = 156 593), HIV-infected lung cancer patients (N = 337) were more frequently young, non-Hispanic black, men, and with distant stage disease. HIV-infected NSCLC patients less frequently received cancer treatment than HIV-uninfected patients [60.3 vs. 77.5%; odds ratio 0.39, 95% confidence interval (CI) 0.30-0.52, after adjustment for diagnosis year, age, sex, race, stage, and histologic subtype]. HIV infection was associated with higher lung cancer-specific mortality (hazard ratio 1.34, 95% CI 1.15-1.56, adjusted for demographics and tumor characteristics). Inclusion of cancer treatment in adjusted models slightly attenuated the effect of HIV on lung cancer-specific mortality (hazard ratio 1.25; 95% CI 1.06-1.47). Also, there was a suggestion that HIV was more strongly associated with mortality among untreated than among treated patients (adjusted hazard ratio 1.32 vs. 1.16, P-interaction = 0.34).
conclusionHIV-infected NSCLC patients were less frequently treated for lung cancer than HIV-uninfected patients, which may have affected survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.